Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neutral-15d-PMJ2 is a synthetic, non-electrophilic analog of the endocannabinoid metabolite 15-deoxy-Δ12,14-prostamide J2 (15d-PMJ2). Developed by researchers at East Carolina University, it serves as a critical research tool for investigating the structure-activity relationship of prostamides in cancer models. The compound is structurally identical to 15d-PMJ2 except for the absence of the electrophilic double bond within its cyclopentenone ring. Research in B16F10 murine melanoma cells has shown that while 15d-PMJ2 induces apoptosis through endoplasmic reticulum (ER) stress and mitochondrial calcium mobilization, neutral-15d-PMJ2 fails to elicit these effects, thereby confirming that the electrophilic moiety is the essential structural component required for the biological activity of the parent molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neutral-15d-PMJ2.